Cipla to distribute Govt allocated stock of COVID drug tocilizumab to states
Fresh limited stock of Covid drug tocilizumab has now been imported and is available with lone marketer company Cipla for marketing and distribution in the country, the letter said.;
New Delhi: The Union government has made an interim allocation of tocilizumab among the states, as a fresh limited stock of the drug used for the treatment of COVID-19 patients has arrived in the country.
In a letter, Pharma Joint Secretary Navdeep Rinwa and Health and Family Welfare Ministry Director Rajiv Wadhawan said the drug went out of stock in the country a few weeks ago due to a sudden surge in its demand because of a sharp rise in COVID-19 cases in the country.
Fresh limited stock of this drug has now been imported and is available with lone marketer company Cipla Ltd for marketing and distribution in the country, the letter said.
"An interim allocation of this drug among states has been finalised by MoHFW (Ministry of Health and Family Welfare) and the DoP (Department of Pharmaceuticals) in consultation with the company," it added.
The allocated stocks have been sent and are being sent to the Cipla depots in the respective states and are "placed at the disposal of the states for the allocation to the government and private hospitals in the state", the letter said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.